H
Hirokazu Ohsawa
Publications - 5
Citations - 166
Hirokazu Ohsawa is an academic researcher. The author has contributed to research in topics: Kinase & EGFR inhibitors. The author has an hindex of 4, co-authored 4 publications receiving 75 citations.
Papers
More filters
Journal ArticleDOI
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Hiroshi Sootome,Hidenori Fujita,Kenjiro Ito,Hiroaki Ochiiwa,Yayoi Fujioka,Kimihiro Ito,Akihiro Miura,Takeshi Sagara,Satoru Ito,Hirokazu Ohsawa,Sachie Otsuki,Kaoru Funabashi,Masakazu Yashiro,Kenichi Matsuo,Kazuhiko Yonekura,Hiroshi Hirai +15 more
TL;DR: Futibatinib is a novel orally available, potent, selective, and irreversible inhibitor of FGFR1–4 with a broad spectrum of antitumor activity in cell lines and xenograft models, supporting clinical evaluation in patients with FGFR-driven tumors.
Journal ArticleDOI
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Shinichi Hasako,Miki Terasaka,Naomi Abe,Takao Uno,Hirokazu Ohsawa,Akihiro Hashimoto,Ryoto Fujita,Kenji Tanaka,Takashige Okayama,Renu Wadhwa,Kazutaka Miyadera,Yoshimi Aoyagi,Kazuhiko Yonekura,Kenichi Matsuo +13 more
TL;DR: Findings support the clinical evaluation of TAS6417 as an efficacious drug candidate for patients with NSCLC harboring EGFR exon 20 insertion mutations.
Journal ArticleDOI
TAS-121, a selective mutant EGFR inhibitor, shows activity against tumors expressing various EGFR mutations including T790M and uncommon mutations G719X
Kimihiro Ito,Makoto Nishio,Masanori Kato,Haruyasu Murakami,Yoshimi Aoyagi,Yuichiro Ohe,Takashige Okayama,Akihiro Hashimoto,Hirokazu Ohsawa,Gotaro Tanaka,Katsumasa Nonoshita,Satoru Ito,Kenichi Matsuo,Kazutaka Miyadera +13 more
TL;DR: TAS-121 is a novel third-generation EGFR-TKI and demonstrates antitumor activities in patients with NSCLC expressing either common or uncommon EGFR mutations, and demonstrates greater selectivity for mutant EGFRs versus the wild-type EGFR compared with other EG FR-TKIs.
Journal ArticleDOI
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Hiroki Irie,Kimihiro Ito,Yayoi Fujioka,Kei Oguchi,Akio Fujioka,Akihiro Hashimoto,Hirokazu Ohsawa,Kenji Tanaka,Kaoru Funabashi,Hikari Araki,Yuichi Kawai,Tadashi Shimamura,Renu Wadhwa,Shuichi Ohkubo,Kenichi Matsuo +14 more
TL;DR: It is demonstrated that TAS0728 may offer a promising therapeutic option with improved efficacy as compared with current HER2 inhibitors for HER2-activated cancers.
Journal ArticleDOI
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Satoru Ito,Sachie Otsuki,Hirokazu Ohsawa,Atsushi Hirano,Hideki Kazuno,Satoshi Yamashita,Kosuke Egami,Yoshihiro Shibata,Ikuo Yamamiya,Fumiaki Yamashita,Yasuo Kodama,Kaoru Funabashi,Hiromi Kazuno,Toshiharu Komori,Satoshi Suzuki,Hiroshi Sootome,H Hirai,Takeshi Sagara +17 more
TL;DR: Futibatinib as mentioned in this paper is a dual inhibitor of mutant epidermal growth factor receptor (FGFR) and FGFR (compound 1), which showed high selectivity for over 387 kinases.